Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Postoperative Radiotherapy in Resected High Risk cSCC-HN
NCT03057613Phase 2Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- May 2017
- Primary completion
- Jun 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in cutaneous squamous cell carcinoma (cSCC), sponsored by Case Comprehensive Cancer Center. Started May 2017; status: completed.
02
Drugs
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT03057613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03057613.